Herantis Pharma Oyj
HRPMF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -1.90 | 0.07 | -0.02 |
| FCF Yield | -9.58% | -8.49% | -18.62% | -31.54% |
| EV / EBITDA | -13.73 | 59.10 | 5.96 | 4.42 |
| Quality | ||||
| ROIC | -258.81% | 3.21% | -178.38% | -172.52% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.32 | -16.57 | 0.96 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -41.18% | 48.17% | 9.96% | -16.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.12 | -6.58 | -0.06 | -0.14 |
| Interest Coverage | -887.83 | 0.28 | -6.00 | -143.59 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |